Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$163 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$-156 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
-1.3
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
184,199,008
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biora Therapeutics Inc (BIOR)
| -67.0 | -9.2 | -42.0 | -77.7 | -- | -- | -- |
|
BSE Sensex*
| 4.0 | -1.2 | 8.0 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Biora Therapeutics Inc (BIOR)
| -60.6 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biora Therapeutics Inc (BIOR)
|
0.7 | 162.9 | 1.0 | -155.9 | -15,251.5 | -- | -- | 0.0 |
| 2.2 | 3.1 | 0.7 | -10.3 | -1,278.2 | -203.6 | -- | 0.0 | |
| 0.3 | 4.6 | 7.5 | -3,074.4 | -146,429.4 | -139.2 | 0 | 1.0 | |
| 119.8 | 12,188.4 | 5,512.6 | 494.7 | 17.0 | 16.3 | 24.9 | 5.6 | |
| 1.2 | 200.2 | 0.0 | -3.3 | -- | -- | -- | 0.0 | |
| 7.5 | 218.0 | 7.0 | -20.0 | -271.4 | -13.4 | -- | 1.5 | |
| 2.6 | 24.1 | 2.9 | -8.4 | -181.0 | -- | -- | 94.8 | |
| 1.8 | 212.0 | 41.6 | -202.0 | -496.2 | -136.3 | -- | 2.0 | |
| 0.5 | 16.8 | 0.0 | -1.0 | -- | -12.4 | 5.4 | 1.8 | |
| 0.9 | 3.4 | 0.0 | -1.0 | -- | -40.9 | -- | 1.2 |
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation... of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California. Read more
Chief Financial Officer
Mr. Eric d'Esparbes
Chief Financial Officer
Mr. Eric d'Esparbes
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biora Therapeutics Inc (BIOR) stood at $ 137 Mln as on 30-Jun-22
The share price of Biora Therapeutics Inc (BIOR) is $0.69 (NASDAQ) as of 08-Jul-2022 09:30 EDT. Biora Therapeutics Inc (BIOR) has given a return of -77.67% in the last 1 years.
Biora Therapeutics Inc (BIOR) has a market capitalisation of $ 163 Mln as on 08-Jul-2022. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Biora Therapeutics Inc (BIOR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biora Therapeutics Inc (BIOR) and enter the required number of quantities and click on buy to purchase the shares of Biora Therapeutics Inc (BIOR).
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
The CEO & director of Mr. Eric d'Esparbes. is Biora Therapeutics Inc (BIOR), and CFO & Sr. VP is Mr. Eric d'Esparbes.
There is no promoter pledging in Biora Therapeutics Inc (BIOR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
20
|
|
|
19
|
|
|
2
|
|
|
2
|
|
|
1
|
|
|
0
|
|
|
0
|
|
|
1,204
|
| Biora Therapeutics Inc (BIOR) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-15251.46
|
|
Net Margin(%)
|
376.16
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Biora Therapeutics Inc (BIOR) was $-156 Mln.
$0.00
(
